CClinicalTrials.gg
CompletedNCT05905302Updated Dec 23, 2025Results posted

The Impact of Exercise on Subthalamic Nucleus Neural Activity in Parkinson's Disease

An interventional study of Forced and Voluntary Exercise in Parkinson Disease and Deep Brain Stimulation, sponsored by Jay Alberts. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-23.

Sponsored by Jay Alberts · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Fifteen PwPD who have undergone DBS surgery and utilize the Percept system will complete a FE and VE exercise session on a stationary cycle while Off antiparkinsonian medication. Bilateral neural activity of the STN will be continuously recorded for 130 minutes (pre-, during FE or VE and post-exercise). The Movement Disorders Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) III Motor Exam and upper extremity force-tracking task will be used to determine motor response to exercise.

Read the detailed description

Parkinson's disease (PD) is a progressive neurological disease, most prevalent in older adults, estimated to affect over 12 million people world-wide by 2040. While antiparkinsonian medication and deep brain simulation (DBS) are effective in managing disease symptoms, disease modification has remained elusive. Exercise has been proposed as the Universal Prescription for PD capable of slowing disease progression; stationary cycling in particular has been suggested as an ideal exercise modality for people with PD (PwPD).Our seminal tandem cycling study was the first to utilize forced exercise (FE) in human PD patients and demonstrate a 30% improvement in clinical ratings compared to voluntary exercise (VE). Briefly, FE is a mode of high intensity exercise originating in animal models of PD in which voluntary exercise rate is augmented, but not replaced. Thus, PwPD were assisted in pedaling at a higher rate (cadence) on the tandem cycle compared to those on a standard stationary cycle performing voluntary exercise (VE). This work resulted in a paradigm shift in terms of recommending high intensity exercise for PwPD. Currently, we are involved in two multi-site clinical trials aimed at identifying the potential of high intensity exercise to slow PD (2R01NS073717 \& 1U01NS113851). Despite the potential of exercise to alter disease progression, its mechanism of action and effects on basal ganglia function are not understood. The loss of dopamine producing neurons associated with PD results in hypersynchrony of basal ganglia motor circuits that underlies PD symptoms. Recent animal studies using FE evaluated neural activity, local field potentials (LFPs), from the primary motor cortex (M1) to estimate the impact of exercise on basal ganglia function. Following FE, neural hypersynchrony in the beta (13-35Hz) frequency band was reduced in M1, which was proposed to underlie improved motor function. M1 activity is impacted by the activity in the subthalamic nucleus (STN), a structure in the basal ganglia, via the direct and indirect pathways. The impact of high intensity exercise, VE or FE, on STN hypersynchrony in humans is unknown. Recording of STN neural activity, until recently, was only possible during DBS surgery or in patients whose electrode was temporarily externalized immediately post-surgery. Neither approach is feasible or safe to systematically evaluate the effects of exercise on basal ganglia function. Recently, the Medtronic Percept DBS platform received FDA approval. The Percept platform records and streams neural activity from the DBS electrode within the STN. This project, for the first time, will record neural activity from the STN during two modes of high intensity exercise, FE and VE, in PwPD to identify the potential mechanism underlying the beneficial effects of exercise on PD. Our underlying hypothesis is that high intensity exercise reduces STN hypersynchrony which facilitates cortico-basal ganglia-thalamocortical circuit functionality thereby improving motor function following exercise.

02

Conditions studied

  • Parkinson Disease
  • Deep Brain Stimulation

Browse trials for

03

In context

Parkinson Disease

4,487 studies on the registry are indexed under Parkinson Disease; 1,082 are open to participants now.

This study's enrollment of 15 is below the median of 40 across 3,294 interventional studies indexed under Parkinson Disease.

Browse Parkinson Disease studies →

Lead sponsor

Jay Alberts is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Adult with a diagnosis of PD by a movement disorders neurologist
  2. Previous placement, at least six months, of bilateral Medtronic Precept DBS as standard of care treatment for their PD.
  3. Stable and clinically optimized DBS parameters for three months prior to enrollment.
  4. Demonstrate the ability to safely mount and dismount a recumbent exercise cycle with an upright back.
  5. Willingness to withhold antiparkinsonian medication and DBS stimulation.
  6. Exercise clearance using the American College of Sports Medicine (ACSM) Pre-participation Health Screen: a. If the ACSM screen recommends medical clearance, the subject must obtain medical clearance by their health care provider prior to participation; b. Those who choose not to obtain physician clearance will not be eligible for participation.

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of dementia or any neurocognitive impairment that compromises the ability to provide informed consent.
  2. A musculoskeletal issue that limits one's ability to cycle
  3. Neurological disease other than Parkinson's disease (i.e. multiple sclerosis, stroke) that impacts motor or cognitive function
  4. Uncontrolled cardiovascular risk factor such as a current cardiac arrhythmia, uncontrolled hypertension, untreated deep vein thrombosis, etc.
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Experimental Arm

    Two modes of high intensity exercise

    Other: Forced and Voluntary Exercise

Interventions

  • OtherForced and Voluntary Exercise

    Participants will complete a forced exercise (FE) and voluntary exercise (VE) session. Forced exercise is a mode of high intensity exercise in which voluntary exercise rate is augmented, but not replaced. Voluntary exercise is standard stationary cycling. FE and VE exercise sessions will be Off antiparkinsonian medication. The order in which exercise session is conducted first will be randomized. Bilateral neural activity of the STN will be continuously recorded for 130 minutes (pre, during FE or VE and post-exercise).

06

What researchers measure

Primary outcomes

  1. Finger Tapping

    Finger tapping portion of the the Movement Disorders Society-Unified Parkinson's Disease Rating Scale subscale III (MDS-UPDRS III). The MDS-UPDRS III assesses motor function in Parkinson's disease using eighteen items scored on a 0-4 scale resulting in a score ranging from 0-72. A higher score (larger number) indicates more motor symptoms. For this outcome, item number 4 (finger tapping rated 0-4) for the participant's dominant hand in the MDS-UPDRS III was analyzed.

    Time frame: Pre- and Post-Exercise

  2. Force Tracking

    Participants were required to modulate the precision grip force of their dominant hand to match a target trajectory on a computer screen. Time within range is the percentage of the trial that participants were within 5% of the target force, with higher values indicating improved accuracy.

    Time frame: Pre- and Post-Exercise

  3. Local Field Potential

    Normalized beta band activity (the change in beta power relative to a resting baseline) is reported as the mean across voluntary exercise (VE) and forced exercise (FE) sessions. The ON DBS condition was not tested for this outcome measure.

    Time frame: Pre- and Post-Exercise

07

Results

Posted Dec 23, 2025

Participant flow

First Intervention (1 day)
Participant flow — First Intervention (1 day)
MilestoneFE Then VEVE Then FE
Started87
Completed87
Not completed00
Washout (at least 1 day)
Participant flow — Washout (at least 1 day)
MilestoneFE Then VEVE Then FE
Started87
Completed87
Not completed00
Second Intervention (1 day)
Participant flow — Second Intervention (1 day)
MilestoneFE Then VEVE Then FE
Started87
Completed87
Not completed00

Outcome measures

PrimaryFinger Tapping

Finger tapping portion of the the Movement Disorders Society-Unified Parkinson's Disease Rating Scale subscale III (MDS-UPDRS III). The MDS-UPDRS III assesses motor function in Parkinson's disease using eighteen items scored on a 0-4 scale resulting in a score ranging from 0-72. A higher score (larger number) indicates more motor symptoms. For this outcome, item number 4 (finger tapping rated 0-4) for the participant's dominant hand in the MDS-UPDRS III was analyzed.

Time frame:
Pre- and Post-Exercise
Reported as:
Median · score on a scale
Finger Tapping
score on a scaleExperimental Arm
ON DBS3 (2 to 3)
Pre-FE OFF DBS3 (3 to 4)
Post-FE OFF DBS3 (2.5 to 3.5)
Pre-VE OFF DBS3 (3 to 4)
Post-VE OFF DBS3 (2.5 to 3)
PrimaryForce Tracking

Participants were required to modulate the precision grip force of their dominant hand to match a target trajectory on a computer screen. Time within range is the percentage of the trial that participants were within 5% of the target force, with higher values indicating improved accuracy.

Time frame:
Pre- and Post-Exercise
Reported as:
Mean · percentage of time within range
Force Tracking
percentage of time within rangeExperimental Arm
ON DBS43.3 ± 23.5
Pre-FE OFF DBS44.9 ± 20.4
Post-FE OFF DBS41.5 ± 21.4
Pre-VE OFF DBS43.0 ± 16.5
Post-VE OFF DBS41.9 ± 16.3
PrimaryLocal Field Potential

Normalized beta band activity (the change in beta power relative to a resting baseline) is reported as the mean across voluntary exercise (VE) and forced exercise (FE) sessions. The ON DBS condition was not tested for this outcome measure.

Time frame:
Pre- and Post-Exercise
Reported as:
Mean · percent power relative to baseline
Local Field Potential
percent power relative to baselineExperimental Arm
Pre-FE OFF DBS Left STN100.0 ± 0.0
Pre-FE OFF DBS Right STN100.0 ± 0.0
Post-FE OFF DBS Left STN131.0 ± 38.3
Post-FE OFF DBS Right STN120.5 ± 34.0
Pre-VE OFF DBS Left STN100.0 ± 0.0
Pre-VE OFF DBS Right STN100.0 ± 0.0
Post-VE OFF DBS Left STN118.8 ± 27.2
Post-VE OFF DBS Right STN110.8 ± 27.7

Adverse events

Collected over Through study completion, an average of 3 days.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pre-FE0/15 (0%)0/15 (0%)0/15 (0%)
Post-FE0/15 (0%)0/15 (0%)0/15 (0%)
Pre-VE0/15 (0%)0/15 (0%)0/15 (0%)
Post-VE0/15 (0%)0/15 (0%)0/15 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)Experimental Arm
Mean67.5 ± 4.8
Sex: Female, Male
Sex: Female, Male(Participants)Experimental Arm
Female6
Male9
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Experimental Arm
Hispanic or Latino1
Not Hispanic or Latino14
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Experimental Arm
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American0
White14
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Experimental Arm
United States15
Duration of Parkinson's disease
Duration of Parkinson's disease(years)Experimental Arm
Mean9.2 ± 3.8
Time since DBS placement
Time since DBS placement(years)Experimental Arm
Median1.5 (0.5 to 10)
08

Study locations

1 site
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
09

References and documents

Publications

  • Koop MM, Rosenfeldt AB, Berki V, Bazyk A, Davidson S, Malan NS, Nagel S, Walter BL, Liao JY, Alberts JL. A novel methodological approach to understanding the cortical and subcortical effects of aerobic exercise in Parkinson's disease. Front Hum Neurosci. 2025 Oct 20;19:1657049. doi: 10.3389/fnhum.2025.1657049. eCollection 2025. PubMed 41189627 ↗

Study documents

  • Protocol and statistical analysis plan · Feb 14, 2023

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No — No individual participant data is being shared.

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05905302
Lead sponsor
Jay Alberts
Responsible party
Jay Alberts (Staff, The Cleveland Clinic) — Sponsor-investigator
First posted
Jun 15, 2023
Start date
Aug 15, 2023
Primary completion
Sep 20, 2024
Completion
Sep 20, 2024
Results posted
Dec 23, 2025
Last update
Dec 23, 2025

Study contacts

Jay Alberts, PhD
principal investigator · Staff

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion